Marion McCourt - Regeneron Pharmaceuticals Senior Vice President and Head of Commercial

REGN -- USA Stock  

USD 285.89  4.27  1.52%

Ms. Marion McCourt is an Senior Vice President and Head of Commercial of the company. She has more than two decades of broad experience in biopharmaceutical management with an emphasis on commercial strategy and execution. She began her biopharmaceutical career with AstraZeneca where she held positions of increasing responsibility over 12 years, ultimately becoming Chief Operating Officer for AstraZeneca U.S. She then held commercial leadership roles at Amgen including Vice President in U.S. Commercial Operations and Vice President and General Manager responsible for the company bone health and primary care business unit. Most recently, Ms. McCourt served as Chief Operating Officer of Medivation until its acquisition by Pfizer in 2016, and as President and Chief Operating Officer of Axovant, a clinicalstage biopharmaceutical company. She holds a B.S. in Biology from Lafayette College.
Age: 58  President Since 2018      

Management Efficiency

The company has return on total asset (ROA) of 11.57 % which means that it generated profit of $11.57 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 24.43 % meaning that it created $24.43 on every $100 dollars invested by stockholders.
The company currently holds 711.3M in liabilities with Debt to Equity (D/E) ratio of 7.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives


Michael PartridgeVertex Pharmaceuticals Incorpor
Glenn DavidZoetis
Charles MilsteinVertex Pharmaceuticals Incorpor
Jatin ShahPerrigo Company plc
Charles WagnerVertex Pharmaceuticals Incorpor
Jeffrey ChodakewitzVertex Pharmaceuticals Incorpor
Stefan WeiskopfZoetis
Cartikeya ReddyDr Reddys Laboratories Ltd
Alok SonigDr Reddys Laboratories Ltd
Michael StewartPerrigo Company plc
Alejandro BernalZoetis
Thomas GraneyVertex Pharmaceuticals Incorpor
J RamachandranDr Reddys Laboratories Ltd
Svend AndersenPerrigo Company plc
Samiran DasDr Reddys Laboratories Ltd
Ian SmithVertex Pharmaceuticals Incorpor
Thomas FarringtonPerrigo Company plc
Raghav ChariDr Reddys Laboratories Ltd
Sripada ChandrasekharDr Reddys Laboratories Ltd
Ganadhish KamatDr Reddys Laboratories Ltd
Marc CouckePerrigo Company plc

Entity Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 7549 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 7,549 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
George Sing, Independent Director
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Stock Performance Indicators

Did you try this?

Run Global Markets Map Now


Global Markets Map

Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
All  Next Launch Module

Currently Active Assets on Macroaxis

Purchased over 20 shares of
1 hour ago
Traded for 135.34
Purchased a lot of shares of
1 hour ago
Traded for 155.87
Purchased over 70 shares of
1 hour ago
Traded for 35.56
Purchased few shares of
1 hour ago
Traded for 174.95
Purchased a lot of shares of
1 hour ago
Traded for 153.01
Additionally take a look at Your Equity Center. Please also try Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.